Innoviva (INVA) Receivables (2012 - 2026)
Innoviva (INVA) posted Receivables of $34.0 million for Q1 2026, down 41.72% on a QoQ basis from $58.4 million in Q4 2025, and up 184.28% year-over-year from $12.0 million in Q1 2025.
Innoviva (INVA) Receivables (2012 - 2026) Analysis & Trends
Innoviva's Receivables history runs 9 years deep, the most recent figure standing at $34.0 million for Q1 2026.
- Quarterly Receivables rose 184.28% year-over-year to $34.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $34.0 million (up 184.28% YoY) and the FY2025 annual result came in at $58.4 million, down 6.38% from the prior year.
- Receivables was $34.0 million for Q1 2026 at Innoviva, down from $58.4 million in the prior quarter.
- Across five years, Receivables topped out at $69.6 million in Q4 2023 and bottomed at $4.4 million in Q3 2022.
- A 5-year average of $41.5 million and a median of $51.4 million in 2024 frame the typical range for Receivables.
- Annual changes were most pronounced in 2023 — Receivables surged 1261.98% — and 2024, when it tumbled 90.31%.
- Innoviva's Receivables stood at $54.7 million in 2022, then rose by 27.34% to $69.6 million in 2023, then slipped by 5.24% to $66.0 million in 2024, then dropped by 11.55% to $58.4 million in 2025, then sank by 41.72% to $34.0 million in 2026.
- Business Quant data shows INVA's Receivables at $34.0 million in Q1 2026, $58.4 million in Q4 2025, and $60.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 4.97 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 938.02 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 1.13 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 2.00 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 5.73 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.93 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Innoviva | 1.57 Bn | 969.11 Mn | 75.83 Mn | 34.01 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 34.01 Mn |
| Dec 31, 2025 | 58.35 Mn |
| Sep 30, 2025 | 60.73 Mn |
| Jun 30, 2025 | 27.00 Mn |
| Mar 31, 2025 | 11.96 Mn |
| Dec 31, 2024 | 65.97 Mn |
| Sep 30, 2024 | 51.40 Mn |
| Jun 30, 2024 | 32.11 Mn |
| Mar 31, 2024 | 6.39 Mn |
| Dec 31, 2023 | 69.62 Mn |
| Sep 30, 2023 | 59.36 Mn |
| Jun 30, 2023 | 20.68 Mn |
| Mar 31, 2023 | 65.96 Mn |
| Dec 31, 2022 | 54.67 Mn |
| Sep 30, 2022 | 4.36 Mn |
| Dec 31, 2021 | 42.49 Mn |
| Dec 31, 2014 | 6.54 Mn |
| Sep 30, 2014 | 4.01 Mn |
| Jun 30, 2014 | 3.47 Mn |
| Mar 31, 2014 | -2.31 Mn |